145 related articles for article (PubMed ID: 11130544)
1. Alosetron for irritable bowel syndrome.
Barbehenn E; Lurie P; Wolfe SM
Lancet; 2000 Dec; 356(9246):2009-10. PubMed ID: 11130544
[No Abstract] [Full Text] [Related]
2. Alosetron: a new therapy for irritable bowel syndrome.
Kupecz D
Nurse Pract; 2000 Jul; 25(7):95-6, 98-100. PubMed ID: 10916831
[No Abstract] [Full Text] [Related]
3. Alosetron in irritable bowel syndrome.
McColl KE
Lancet; 2000 Jul; 356(9224):164-5. PubMed ID: 10963271
[No Abstract] [Full Text] [Related]
4. Alosetron (Lotronex) for treatment of irritable bowel syndrome.
Med Lett Drugs Ther; 2000 Jun; 42(1081):53-4. PubMed ID: 10872030
[No Abstract] [Full Text] [Related]
5. Alosetron approved for treatment of irritable bowel syndrome.
Miller JL
Am J Health Syst Pharm; 2000 Mar; 57(6):519. PubMed ID: 10754758
[No Abstract] [Full Text] [Related]
6. Neurotransmitter antagonism in management of irritable bowel syndrome.
Lembo T
Lancet; 2000 Mar; 355(9209):1030-1. PubMed ID: 10744083
[No Abstract] [Full Text] [Related]
7. Review article: clinical pharmacology of alosetron.
Gunput MD
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():70-6. PubMed ID: 10429744
[TBL] [Abstract][Full Text] [Related]
8. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.
Delvaux M; Louvel D; Mamet JP; Campos-Oriola R; Frexinos J
Aliment Pharmacol Ther; 1998 Sep; 12(9):849-55. PubMed ID: 9768527
[TBL] [Abstract][Full Text] [Related]
9. [Soon one "female distress" less. Irritable bowel syndrome responds to serotonin blockers].
MMW Fortschr Med; 2000 Sep; 142(37):55. PubMed ID: 11026224
[No Abstract] [Full Text] [Related]
10. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients.
Mangel AW; Northcutt AR
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():77-82. PubMed ID: 10429745
[TBL] [Abstract][Full Text] [Related]
11. [New therapeutic approaches in irritable bowel syndrome].
Müller-Lissner SA
Z Gastroenterol; 2000 Sep; 38(9):815-6. PubMed ID: 11072681
[No Abstract] [Full Text] [Related]
12. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.
Houghton LA; Foster JM; Whorwell PJ
Aliment Pharmacol Ther; 2000 Jun; 14(6):775-82. PubMed ID: 10848662
[TBL] [Abstract][Full Text] [Related]
13. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers.
Clemens CH; Samsom M; Van Berge Henegouwen GP; Fabri M; Smout AJ
Aliment Pharmacol Ther; 2002 May; 16(5):993-1002. PubMed ID: 11966509
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
Camilleri M; Northcutt AR; Kong S; Dukes GE; McSorley D; Mangel AW
Lancet; 2000 Mar; 355(9209):1035-40. PubMed ID: 10744088
[TBL] [Abstract][Full Text] [Related]
15. New drugs to treat irritable bowel syndrome being tested.
Mayo Clin Health Lett; 2000 Mar; 18(3):4. PubMed ID: 10734837
[No Abstract] [Full Text] [Related]
16. Tegaserod and other serotonergic agents: what is the evidence?
Chey WD
Rev Gastroenterol Disord; 2003; 3 Suppl 2():S35-40. PubMed ID: 12776001
[TBL] [Abstract][Full Text] [Related]
17. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.
Watson ME; Lacey L; Kong S; Northcutt AR; McSorley D; Hahn B; Mangel AW
Am J Gastroenterol; 2001 Feb; 96(2):455-9. PubMed ID: 11232690
[TBL] [Abstract][Full Text] [Related]
18. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
Thumshirn M; Coulie B; Camilleri M; Zinsmeister AR; Burton DD; Van Dyke C
Aliment Pharmacol Ther; 2000 Jul; 14(7):869-78. PubMed ID: 10886042
[TBL] [Abstract][Full Text] [Related]
19. Irritable bowel syndrome. New treatment drug on the market.
Harv Health Lett; 2000 Jun; 25(8):7. PubMed ID: 10810051
[No Abstract] [Full Text] [Related]
20. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
Lembo T; Wright RA; Bagby B; Decker C; Gordon S; Jhingran P; Carter E;
Am J Gastroenterol; 2001 Sep; 96(9):2662-70. PubMed ID: 11569692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
